| Predicting risk and treatment benefit in atherosclerosis: the role of C-reactive protein. | |
| | |
MedLine Citation:
|
PMID: 15686768 Owner: NLM Status: MEDLINE |
Abstract/OtherAbstract:
|
Inflammatory mechanisms play a prominent role in mediating all stages of atherosclerosis, and measurement of inflammatory biomarkers provides a method for detecting individuals at future vascular risk. Evidence from observational studies indicates that the hepatic acute-phase reactant, C-reactive protein (CRP), is the strongest predictor of future myocardial infarction and stroke. The addition of CRP to standard lipid screening may improve global risk prediction among those with high as well as low cholesterol. Statins have been shown to have beneficial effects on plaque inflammation, stability and CRP levels, in addition to their lipid-lowering effects. Data from two large statin trials suggest that testing for CRP may identify many individuals without hyperlipidaemia who are at high risk for future cardiovascular events and who may benefit from statin therapy. If confirmed in ongoing large-scale prospective trials, screening for inflammation using CRP as a biomarker could prove an important adjunctive method for identifying individuals at increased risk who would benefit most from targeted preventive interventions. |
| | |
Authors:
|
Wolfgang Koenig |
Related Documents
:
|
16238678 - Distribution and determinants of serum high-sensitive c-reactive protein in a populatio... 22499448 - Screening for frailty in elderly emergency department patients by using the identificat... 19375128 - Metabolic syndrome and c-reactive protein in stroke prediction: a prospective study in ... 16614428 - Prevalence of daidzein-metabolizing phenotypes differs between caucasian and korean ame... 9286728 - Androgen serum levels in women with premature ovarian failure compared to fertile and m... 23197168 - Potent antiretroviral therapy for human immunodeficiency virus infection increases aort... |
Publication Detail:
|
Type: Journal Article; Review |
Journal Detail:
|
Title: International journal of cardiology Volume: 98 ISSN: 0167-5273 ISO Abbreviation: Int. J. Cardiol. Publication Date: 2005 Feb |
Date Detail:
|
Created Date: 2005-02-02 Completed Date: 2005-05-26 Revised Date: 2007-11-15 |
Medline Journal Info:
|
Nlm Unique ID: 8200291 Medline TA: Int J Cardiol Country: Ireland |
Other Details:
|
Languages: eng Pagination: 199-206 Citation Subset: IM |
Affiliation:
|
Department of Internal Medicine II-Cardiology, University of Ulm Medical Center, Robert-Koch Strasse 8, D-89081 Ulm, Germany. wolfgang.koenig@medizin.uni-ulm.de |
Export Citation:
|
APA/MLA Format Download EndNote Download BibTex |
| MeSH Terms | |
Descriptor/Qualifier:
|
Biological Markers
/
blood* C-Reactive Protein / analysis* Cardiovascular Diseases / blood, epidemiology Coronary Artery Disease / diagnosis*, physiopathology Humans Hydroxymethylglutaryl-CoA Reductase Inhibitors / pharmacology, therapeutic use Risk Assessment Risk Factors |
| Chemical | |
Reg. No./Substance:
|
0/Biological Markers; 0/Hydroxymethylglutaryl-CoA Reductase Inhibitors; 9007-41-4/C-Reactive Protein |
From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine
Previous Document: Diagnostic value of stress echocardiography for the detection of restenosis after PTCA.
Next Document: Electrophysiological evaluation of asymptomatic ventricular pre-excitation in children and adolescen...